ALKERMES | ALKS - Ativo Circulante





Ativo Circulante Alterar Data
AbbVie USD 33.53B 4.47B 2026-03
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Coherus Biosciences USD 206.71M 254.25M 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Heron Therapeutics USD 228.98M 9.08M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
J&J USD 59.17B 3.55B 2026-03
Malin Corporation EUR 62.6M 26.7M 2024-12
Merck USD 35.02B 8.5B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Otsuka Holdings JPY 1.6T 21.76B 2026-03
Ovoca Bio EUR 1.56M 3.39M 2025-06
Pfizer USD 42.82B 76M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03